Fabino Life Sciences Ltd. engages in the manufacture and trading of pharmaceutical, allopathic, herbal, veterinary, and other wellness focused consumer products. The company is headquartered in New Delhi, Delhi. The company went IPO on 2022-01-13. The firm offers a range of allopathic and herbal products. Its product categories include allopathic products, Covid-19 products, food supplements, herbal products, multi-vitamin products, and veterinary products. Its allopathic products include AMOXRAG-625, Astrid Syrup, Aurceta AM, Aurifox OZ, Aurirug 200, Aurirug O, Aurnim Plus, Aurstin 250, Ceporag O, Doref M, Dr-DSR, F Plexus A, and Fabpara. Its Covid-19 products include disposable face shield, fabclean hand sanitizer, mask, and personal protective equipment (PPE). Its herbal products include Aurcis-Forte, Aurzyme-Syrup, Ayush Kadha, Coptec-syrup, Cough-Free, DStoren-Syrup, Ecstasy Tilla Oil, Fablactin, Giloy Power, Keepshine Hair Oil, Onion Hair Oil, Pain-Go, Power Malt, Regaliv-ds, Sandy Forte and M-Sharp-Brain-tonic. Its Multi-Vitamin products include Aur D3 Capsules, Coptec Capsules, FABZYM CAPSULE, Oshnine Plus, and Rigovit Softgel Capsules.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.
17 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.